PD-1/PDL-1 directed monoclonal antibodies were recently developed and demonstrated promising anti-cancer activity [23], but were strongly associated with immune-related adverse events, including the induction of BP, which was proved morphologically and immunopathologically indistinguishable from typical BP [16]. The gene discussed is CD274; the disease is cancer.